Immunoserological aspects of idiopathic inflammatory muscle disease

Citation
B. Rozman et al., Immunoserological aspects of idiopathic inflammatory muscle disease, WIEN KLIN W, 112(15-16), 2000, pp. 722-727
Citations number
25
Categorie Soggetti
General & Internal Medicine
Journal title
WIENER KLINISCHE WOCHENSCHRIFT
ISSN journal
00435325 → ACNP
Volume
112
Issue
15-16
Year of publication
2000
Pages
722 - 727
Database
ISI
SICI code
0043-5325(20000825)112:15-16<722:IAOIIM>2.0.ZU;2-0
Abstract
In the present study, the autoantibody profile of 31 Slovenian patients wit h idiopathic inflammatory muscle disease was estimated: 11 with polymyositi s, 11 with dermatomyositis - both groups diagnosed according to the criteri a of Bohan and Peter - and 9 with myositis-overlap syndromes. Autoantibodies against most relevant muscle specific (Jo-1, Mi-2) and non-s pecific antigens (PM-Scl, U1RNP, native Ro, Ro60, Ro52, and La) were detect ed with one or more detection techniques: counter-immunoelectrophoresis, en zyme-linked immunoassay, immunoblot and immunoprecipitation, each using dif ferent antigen preparations (native, recombinant). With counter-immunoelect rophoresis using a native antigen substrate (rabbit thymus extract), we wer e able to detect anti-PM-Scl antibodies more readily than with other techni ques, probably due to conformational epitopes of native PM-Scl. Patients wi th this serological profile constituted a distinct group, sharing features of polymyositis and systemic sclerosis. Compared to previously reported data, the greater frequency of anti-Jo-1 fo und in all groups of patients (64-87% for PM, 18-20% for dermatomyositis an d 33-44% for overlap syndromes) was probably due to the various methods use d and the different clinical characteristics of patients. The greater preva lence of anti-Mi-2 antibodies in dermatomyositis patients (67%) and in part icular in polymyositis patients (33%) and myositis-overlap syndromes (33%) seemed to be mainly due to methodological differences. A strikingly high prevalence of anti-Ro52 positive patients with polymyosit is (55%), dermatomyositis (22%), and myositis-overlap syndromes (33%) was d emonstrated, but was detected by only one technique. Moreover, concurrence with anti-Jo-1 antibodies was noted (69%).